CN1353603A - 控制与治疗药物有关的体重增加的方法 - Google Patents
控制与治疗药物有关的体重增加的方法 Download PDFInfo
- Publication number
- CN1353603A CN1353603A CN00807688A CN00807688A CN1353603A CN 1353603 A CN1353603 A CN 1353603A CN 00807688 A CN00807688 A CN 00807688A CN 00807688 A CN00807688 A CN 00807688A CN 1353603 A CN1353603 A CN 1353603A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- cyclobutyl
- chlorphenyl
- methyl butyl
- chinese style
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 32
- 230000004584 weight gain Effects 0.000 title abstract 2
- 235000019786 weight gain Nutrition 0.000 title abstract 2
- 229940126585 therapeutic drug Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 73
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 10
- -1 sulphonylureas Substances 0.000 claims abstract description 8
- 238000002651 drug therapy Methods 0.000 claims abstract description 6
- 150000004682 monohydrates Chemical class 0.000 claims abstract description 6
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 claims abstract description 5
- 102000004877 Insulin Human genes 0.000 claims abstract description 5
- 108090001061 Insulin Proteins 0.000 claims abstract description 5
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000002876 beta blocker Substances 0.000 claims abstract description 5
- 239000003433 contraceptive agent Substances 0.000 claims abstract description 5
- 239000003246 corticosteroid Substances 0.000 claims abstract description 5
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960001140 cyproheptadine Drugs 0.000 claims abstract description 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940125396 insulin Drugs 0.000 claims abstract description 5
- 229910052744 lithium Inorganic materials 0.000 claims abstract description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 5
- 229950000688 phenothiazine Drugs 0.000 claims abstract description 5
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims abstract description 5
- 229940084026 sodium valproate Drugs 0.000 claims abstract description 5
- 150000003431 steroids Chemical class 0.000 claims abstract description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 18
- 229960004170 clozapine Drugs 0.000 claims description 12
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 10
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- HQABUPZFAYXKJW-UHFFFAOYSA-N N-butylamine Natural products CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 claims description 7
- 229940100389 Sulfonylurea Drugs 0.000 claims description 4
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 claims description 4
- 230000002254 contraceptive effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960001078 lithium Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000607 ziprasidone Drugs 0.000 claims description 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims description 3
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims description 2
- PQJUJGAVDBINPI-UHFFFAOYSA-N 9H-thioxanthene Chemical compound C1=CC=C2CC3=CC=CC=C3SC2=C1 PQJUJGAVDBINPI-UHFFFAOYSA-N 0.000 claims description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 2
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 2
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 claims description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 2
- 229960001076 chlorpromazine Drugs 0.000 claims description 2
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims description 2
- 229960002419 flupentixol Drugs 0.000 claims description 2
- 229960002690 fluphenazine Drugs 0.000 claims description 2
- 229960003878 haloperidol Drugs 0.000 claims description 2
- 229960005017 olanzapine Drugs 0.000 claims description 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 2
- 150000002990 phenothiazines Chemical class 0.000 claims description 2
- 229960001534 risperidone Drugs 0.000 claims description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 2
- 229960004940 sulpiride Drugs 0.000 claims description 2
- 229960002784 thioridazine Drugs 0.000 claims description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 2
- 229960002324 trifluoperazine Drugs 0.000 claims description 2
- 229960004496 zotepine Drugs 0.000 claims description 2
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 claims description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 abstract 1
- UWAOJIWUVCMBAZ-UHFFFAOYSA-N [1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl]-dimethylazanium;chloride Chemical compound Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UWAOJIWUVCMBAZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940124558 contraceptive agent Drugs 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 abstract 1
- 229960004425 sibutramine Drugs 0.000 description 14
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 13
- 239000002552 dosage form Substances 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 208000028659 discharge Diseases 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000000407 monoamine reuptake Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000012053 oil suspension Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- 229960001058 bupropion Drugs 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- BMFVGAAISNGQNM-UHFFFAOYSA-N isopentylamine Chemical compound CC(C)CCN BMFVGAAISNGQNM-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960004688 venlafaxine Drugs 0.000 description 2
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-CMIMLBRMSA-N 4-[(1r)-2-amino-1-hydroxy-1-tritioethyl]benzene-1,2-diol Chemical compound NC[C@@](O)([3H])C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-CMIMLBRMSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229950010118 cellacefate Drugs 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 238000004460 liquid liquid chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 229960003466 sibutramine hydrochloride Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000006208 topical dosage form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
式(I)化合物或其可药用盐用于治疗与某些药物治疗有关的体重增加,式(I)中R1和R2独立地为H或甲基(例如N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐,任选地为其一水合物形式),所述药物治疗包括用下列药物治疗:三环抗抑郁药、锂、磺酰脲类、β-肾上腺素能阻断剂、某些甾族避孕药、皮质类固醇、胰岛素、二苯环庚啶、丙戊酸钠、精神抑制剂、吩噻嗪和培替芬。
Description
本发明涉及控制与药物治疗有关的体重增加的方法。
某些治疗药物的应用可以促进体重增加。这些药物包括三环抗抑郁药、锂、磺酰脲类、β-肾上腺素能阻断剂、某些甾族避孕药、皮质类固醇、胰岛素、二苯环庚啶、丙戊酸钠、培替芬(piztifen)、精神抑制剂包括典型的精神抑制剂例如吩噻嗪和吩噻嗪衍生物例如氯丙嗪、硫利达嗪、氟奋乃静和三氟拉嗪;丁酰苯例如氟哌啶醇;噻吨例如氟哌噻吨和取代的苯甲酰胺例如舒必利、非典型的精神抑制剂包括氯氮平、奥氮平、佐替平、利司培酮、奎泰平(quetiapine)和齐普拉西酮(ziprasidone)。
优选的式I化合物是N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺或其盐,例如盐酸盐。优选的盐酸盐是其一水合物。
在英国专利说明书GB 2098602和美国专利US4,522,328中描述了式I化合物的制备以及它们在治疗抑郁症中的应用,所述式I化合物是例如N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺、N-{1-[1-(4-氯苯基)-环丁基]-3-甲基丁基}-N-甲基胺和1-[1-(4-氯苯基)-环丁基]-3-甲基丁基胺及其盐。式I化合物例如N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺及其盐在治疗帕金森氏病中的应用描述于公开的PCT申请WO88/06444。在美国专利US4,939,175中描述了N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺及其盐在治疗脑机能障碍中的应用。在公开的PCT申请WO90/06110中描述了N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐在治疗肥胖中的应用。该化合物特别优选的形式是N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐一水合物(盐酸西布曲明),该物质描述于欧洲专利EP 230742中。在公开的PCT申请WO 95/20949中描述了N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺及其盐在改善患有葡萄糖耐量障碍或非胰岛素依赖型糖尿病患者的葡萄糖耐量中的应用。
式I化合物含有手性中心对于本领域专业人员来说将是显而易见的。当式I化合物含有单一手性中心时,它可以存在两种对映异构形式。本发明包括每种对映体以及对映体的混合物的应用。可以按照本领域专业人员已知的方法拆分对映体,例如形成可分离的非对映异构的盐或配合物,例如通过结晶法分离;形成可分离的非对映异构的衍生物,例如通过结晶法、气-液色谱或液相色谱法分离;一种对映体与一种对映体专一的试剂进行选择性反应,例如酶促氧化或还原,然后分离修饰的和未修饰的对映体;或者在手性环境中进形气-液或液相色谱,例如在手性载体如结合有手性配体的二氧化硅上或者在手性溶剂存在下进行。显然,如果通过上述一种分离方法将所需的对映体转化为另一种化学物质,则需要另一步骤以释放出所需的对映异构形式。或者,可以通过使用旋光活性试剂、底物、催化剂或溶剂进行不对称合成,或者通过不对称转化将一种对映体转化为另一种对映体,合成特定的对映体。
优选的式I化合物是N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺、N-{1-[1-(4-氯苯基)环丁基]-3-甲基丁基}-N-甲基胺和1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺,包括外消旋体、单个对映体及其混合物,以及其可药用的盐。
可以通过由旋光活性前体对映选择合成,或者通过拆分可如上所述制备的外消旋化合物,制备单个对映体。还可以如下制备式I仲胺的对映体:制备相应伯胺的外消旋体、将外消旋体拆分成单个对映体、然后将旋光纯的伯胺对映体转化为所需的仲胺,如通过英国专利说明书GB 2098602所述的方法。
式I化合物的具体实例是:(+)-N-[1-[1-(4-氯苯基)环丁基]-3-甲基丁基}-N-甲基胺;(-)-N-{1-[1-(4-氯苯基)环丁基-3-甲基丁基}-N-甲基胺;(+)-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺;(-)-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺;(+)-N-{1-[1-(4-氯苯基)环丁基]-3-甲基丁基}-N,N-二甲基胺;(-)-N-{1-[1-(4-氯苯基)环丁基]-3-甲基丁基}-N,N-二甲基胺。
在每种情况下,盐酸盐均是优选的,当然游离碱及其它可药用盐也是适用的。
式I化合物可以以任何已知的药物剂型给药。化合物的给药量取决于多种因素,包括患者的年龄、患者疾病的严重程度以及既往的医疗史,并且总是落在给药医生的合理考虑范围内,但是通常该化合物的给药剂量为每天0.1-50mg,优选1-30mg,每天一次或分数次给药。
口服剂型是本发明应用的优选组合物,用于这种给药方式的已知药物剂型是例如片剂、胶囊、粒剂、糖浆和水悬浮液或油悬浮液。这些组合物制备中所用的赋形剂是药物制剂领域已知的赋形剂。片剂可以由活性化合物与下列物质的混合物制备,所述物质包括填料例如磷酸钙;崩解剂例如玉米淀粉;润滑剂例如硬脂酸镁;粘合剂例如微晶纤维素或聚乙烯吡咯烷酮以及其他本领域已知的、可按照已知方法将混合物压片的任选成分。如果需要,可以采用已知方法和赋形剂将片剂包衣,包括使用例如邻苯二甲酸羟丙基甲基纤维素进行肠溶包衣。可以按照本领域专业人员已知的方法配制片剂,以使本发明化合物持续释放。如果需要,可以采用已知方法,例如使用乙酸邻苯二甲酸纤维素进行肠溶包衣。类似地,可以按照已知方法制备含有活性化合物的胶囊,例如硬或软明胶胶囊,其中加有或者不加赋形剂,并且如果需要,可以按照已知方法包肠溶衣。可以按照已知方法配制胶囊的成分以使活性化合物持续释放。每片或者每粒胶囊通常可以含有1-50mg活性化合物。
其它口服剂型包括例如在水性基质中含有活性化合物的水悬浮液,其中含有无毒悬浮剂例如羧甲基纤维素钠,以及在合适的植物油例如花生油中含有本发明化合物的油悬浮液。可以将活性化合物制备成含有或不含其它赋形剂的颗粒。患者可以直接将颗粒咽下,或者可以将颗粒加入适宜的液体载体(例如水)中服下。颗粒可以含有崩解剂例如由酸和碳酸盐或碳酸氢盐形成的泡腾对,以便于其分散在液体基质中。
可以将治疗活性的式I化合物配制成患者口含的组合物,以便将活性化合物经口腔粘膜给药。
适于直肠给药的剂型是已知的药物剂型,例如含有可可脂或聚乙二醇基质的栓剂。
适用于非肠道给药的剂型是已知的这种给药形式的药物剂型,例如在合适溶剂中的无菌悬浮液或无菌溶液。
局部给药剂型可以包括分散有本发明药理活性化合物的基质,以便保持活性化合物与皮肤的接触,从而经皮施用该化合物。合适的透皮组合物可以通过下述方法制备:将药物活性化合物与局部赋形剂例如矿物油、凡士林和/或蜡例如石蜡或蜂蜡以及可能的透皮促进剂例如二甲基亚砜或丙二醇混合。或者,将活性化合物分散在可药用乳膏、凝胶或软膏基质中。局部制剂中活性化合物的含量应该是在该局部制剂计划在皮肤上保留的时间内释放治疗有效量化合物的量。
可以将治疗活性的式I化合物制备成以气溶胶形式散布到患者口腔或鼻腔中的组合物。该气溶胶可以通过泵装置或者含有挥发性抛射剂的加压装置给药。
用于本发明方法的治疗活性的式I化合物还可以通过连续的输注给药,可以是外部给药,例如静脉内输注,也可以是由置于体内的化合物来源给药。内部来源包括植入的含有待注入的化合物的药物储库,其中的化合物可通过例如渗透连续释放,以及植入物,该植入物可以是(a)液体例如待注入的化合物的油悬浮液,例如极少溶于水的衍生物形式如十二烷酸盐或亲脂性酯,或是(b)待注入的化合物的植入载体形式的固体,例如合成树脂或蜡状材料。载体可以是含有所有化合物的单一个体,也可以是各含一部分待释放化合物的一系列数个个体。内部来源中活性化合物的含量应该是在长时间内释放治疗有效量化合物的量。
在某些制剂中,使用非常小尺寸颗粒形式的本发明化合物是有益的,例如通过液能磨机获得的颗粒。
如果需要,在本发明组合物中,可以将活性化合物与其它相容的药理活性成分结合。
本发明还提供了式I化合物在制备控制与某些已知引起体重增加的治疗药物有关的患者体重增加的药物中的应用。
另一方面,本发明还提供了药物组合物,该组合物用于预防接受下列药物治疗患者的体重增加:三环抗抑制药、锂、磺酰脲类、β-肾上腺素能阻断剂、某些甾族避孕药、皮质类固醇、胰岛素、二苯环庚啶、丙戊酸钠、精神抑制剂、吩噻嗪和培替芬,该组合物含有与可药用稀释剂或载体结合的式I化合物。
一元胺摄取抑制剂已经用于治疗某些本发明所述的疾病。但是,已知这些化合物有很多不利之处。首先,这些化合物不是对所有患者均有效。第二,化合物有效、但是不能完全治愈疾病。第三,该类化合物有很多已知的不希望的副作用。所述副作用包括恶心、性机能障碍、头昏目眩、瞌睡、出汗、震颤、口干、无力、失眠、腹泻、头痛、呕吐、焦虑、倦睡、头晕、发热、疹或变应性反应、关节痛、肌痛、惊厥、轻症躁狂和躁狂。
西布曲明(式I,R1=CH3,R2=CH3)具有在一元胺摄取抑制剂中独一无二的药理学特性。通过其药理活性代谢物(代谢物1,在式I中R1=H、R2=CH3,和代谢物2,在式I中R1=H、R2=H),西布曲明抑制所有三种一元胺的摄取,它们分为5-羟色胺(5-HT)-选择性摄取抑制剂例如氟西汀、去甲肾上腺素选择性摄取抑制剂例如去郁敏、多巴胺选择性摄取抑制剂例如安非他酮和5-羟色胺去甲肾上腺素摄取抑制剂例如文拉法辛(表1)。这种药理学作用独特的结合使得西布曲明以及其他式I化合物可以有效地控制与某些已知引起体重增加的治疗药物有关的体重增加。
按照与WO98/41528中所述类似的方法进行下列分析。
表实施例1和2以及各种参照一元胺摄取抑制剂在大鼠脑组织中的体外一元胺摄取抑制特性的比较
Ki(nM) | |||
[3H]去甲肾上腺素 | [3H]5-HT | [3H]多巴胺 | |
实施例1 | 3 | 18 | 24 |
实施例2 | 5 | 26 | 31 |
安非他酮 | 2590 | 18312 | 409 |
去都敏 | 2 | 200 | 4853 |
氟西汀 | 320 | 11 | 2025 |
文拉法辛 | 196 | 26 | 2594 |
结果是≥3次独立测定的平均值
实施例1在式I中R1=H、R2=CH3
实施例2在式I中R1=H、R2=H
通过下列实验证明了式I化合物在治疗与某些药物治疗有关的体重增加中的功效。
使用单独饲养的雌性Sprague-Dawley大鼠进行实验,大鼠可以在任何时间自由取得食物(含20%猪油的粉状大鼠食物)和自来水。在开始实验那天,给动物(n=10)口服赋形剂;精神抑制剂氯氮平3mg/kg;西布曲明3mg/kg或西布曲明加氯氮平3mg/kg;并且监测动物2小时内的食物摄取情况。与赋形剂处理的对照组相比,氯氮平(3mg/kg)使食物的摄取明显增加(表1)。与对照组相比,口服西布曲明(3mg/kg)明显降低食物的摄取。西布曲明同时给药防止由氯氮平引起的食物摄取增加。实际上,同时给予西布曲明和氯氮平的动物吃进食物的量与只给予西布曲明的大鼠类似(表1)。这些结果证明西布曲明预防氯氮平引起的大鼠饮食过多,并且表明西布曲明将在临床上有效地控制与精神抑制剂有关的体重增加。
表1西布曲明预防氯氮平引起的大鼠饮食过多
治疗 | 平均食物摄取(g/kg)±SEM |
赋形剂 | 6.5±0.9 |
氯氮平3mg/kg | 9.3±0.7* |
西布曲明3mg/kg | 1.7±0.6** |
氯氮平3mg/kg加西布曲明3mg/kg | 2.1±0.5** |
与赋形剂处理的对照组有显著差异的以*P<0.01、**P<0.001表示。氯氮平引起的饮食过多的显著拮抗作用以P<0.001表示(Dunnett’s实验;双尾实验)。
通过在相关人群组中进行临床实验证明了式I化合物在治疗与某些药物治疗有关的体重增加中的功效。
虽然已经参照各个具体实施方案对本发明进行了描述,但是在本发明的范围和精神内可以进行许多变化和改进。
Claims (20)
2.权利要求1的方法,其中药物治疗是用下列药物治疗:三环抗抑郁药、锂、磺酰脲类、β-肾上腺素能阻断剂、甾族避孕药、皮质类固醇、胰岛素、二苯环庚啶、丙戊酸钠、培替芬、精神抑制剂,包括典型的精神抑制剂例如吩噻嗪和吩噻嗪衍生物例如氯丙嗪、硫利达嗪、氟奋乃静和三氟拉嗪;丁酰苯类例如氟哌啶醇;噻吨例如氟哌噻吨和取代的苯甲酰胺例如舒必利、非典型的精神抑制剂,包括氯氮平、奥氮平、佐替平、利司培酮、奎泰平和齐普拉西酮。
3.权利要求1或2的方法,其中式I化合物是N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐。
4.权利要求1或2的方法,其中式I化合物是N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐一水合物。
5.权利要求1或2的方法,其中式I化合物是(+)-N-[1-[1-(4-氯苯基)环丁基]-3-甲基丁基}-N-甲基胺。
6.权利要求1或2的方法,其中式I化合物是(-)-N-{1-[1-(4-氯苯基)环丁基-3-甲基丁基}-N-甲基胺。
7.权利要求1或2的方法,其中式I化合物是(+)-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺。
8.权利要求1或2的方法,其中式I化合物是(-)-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺。
9.权利要求1或2的方法,其中式I化合物是(+)-N-{1-[1-(4-氯苯基)环丁基]-3-甲基丁基}-N,N-二甲基胺。
10.权利要求1或2的方法,其中式I化合物是(-)-N-{1-[1-(4-氯苯基)环丁基]-3-甲基丁基}-N,N-二甲基胺。
11.权利要求1或2的方法,其中式I化合物是(±)-N-{1-[1-(4-氯苯基)环丁基]-3-甲基丁基}-N-甲基胺。
12.权利要求1或2的方法,其中式I化合物是(±)-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺。
13.权利要求1或2的方法,其中式I化合物是(±)-N-{1-[1-(4-氯苯基)环丁基]-3-甲基丁基}-N,N-二甲基胺。
15.权利要求14的应用,其中药物治疗是用下列药物的治疗:三环抗抑郁药、锂、磺酰脲类、β-肾上腺素能阻断剂、某些甾族避孕药、皮质类固醇、胰岛素、二苯环庚啶、丙戊酸钠、精神抑制剂、吩噻嗪和培替芬。
16.权利要求14或15的应用,其中式I化合物是N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐。
17.权利要求14或15的应用,其中式I化合物是N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐一水合物。
18.用于治疗与某些药物治疗有关的体重增加的药物组合物,其中含有治疗有效量的式I化合物,包括其对映体和可药用盐,和可药用的稀释剂或载体,其中R1和R2独立地为H或甲基。
19.权利要求18的药物组合物,其中式I化合物是N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐。
20.权利要求18的药物组合物,其中式I化合物是N,N-二甲基-1-[1-(4-氯苯基)环丁基]-3-甲基丁基胺盐酸盐一水合物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12534099P | 1999-03-19 | 1999-03-19 | |
US60/125,340 | 1999-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1353603A true CN1353603A (zh) | 2002-06-12 |
Family
ID=22419292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN00807688A Pending CN1353603A (zh) | 1999-03-19 | 2000-03-17 | 控制与治疗药物有关的体重增加的方法 |
Country Status (20)
Country | Link |
---|---|
US (1) | US6376552B1 (zh) |
EP (1) | EP1162965A1 (zh) |
JP (1) | JP2002539251A (zh) |
KR (1) | KR20020000784A (zh) |
CN (1) | CN1353603A (zh) |
AU (1) | AU3757800A (zh) |
BG (1) | BG105997A (zh) |
BR (1) | BR0009159A (zh) |
CA (1) | CA2367021A1 (zh) |
CZ (1) | CZ291864B6 (zh) |
HU (1) | HUP0200393A2 (zh) |
IL (1) | IL145241A0 (zh) |
MX (1) | MXPA01009467A (zh) |
NO (1) | NO20014480L (zh) |
NZ (1) | NZ514009A (zh) |
PL (1) | PL350919A1 (zh) |
SK (1) | SK13352001A3 (zh) |
TR (1) | TR200102695T2 (zh) |
WO (1) | WO2000056313A1 (zh) |
ZA (1) | ZA200107692B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101626768B (zh) * | 2006-09-15 | 2013-08-21 | 雷维瓦药品公司 | 环烷基甲胺的合成、使用方法和组合物 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002019998A2 (en) * | 2000-09-08 | 2002-03-14 | Eli Lilly And Company | A method of treating weight gain associated with atypical antipsychotic use |
RU2290924C2 (ru) * | 2002-10-05 | 2007-01-10 | Ханми Фарм. Ко., Лтд. | Фармацевтическая композиция, включающая кристаллический полугидрат метансульфоната сибутрамина |
US20050131074A1 (en) * | 2003-08-04 | 2005-06-16 | Beckman Kristen M. | Methods for treating metabolic syndrome |
US20060035827A1 (en) * | 2004-06-24 | 2006-02-16 | Green Gary M | Compositions and methods for the treatment or prevention of gallbladder disease |
KR20060080818A (ko) | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 술폰산염 |
KR20060080817A (ko) | 2005-01-06 | 2006-07-11 | 씨제이 주식회사 | 시부트라민의 디카복실산염 |
EP1846359A4 (en) * | 2005-01-06 | 2010-03-31 | Cj Cheiljedang Corp | INORGANIC ACID SALTS OF SIBUTRAMINE |
KR20060093564A (ko) * | 2005-02-22 | 2006-08-25 | 종근당바이오 주식회사 | 무수 시부트라민 말산염 및 이의 제조 방법 |
KR100627687B1 (ko) * | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
EP2083867A1 (en) * | 2006-11-22 | 2009-08-05 | SK Chemicals, Co., Ltd. | Inclusion complex of sibutramine and beta-cyclodextrin |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2675573B2 (ja) * | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
US5459164A (en) | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
-
2000
- 2000-03-17 US US09/527,962 patent/US6376552B1/en not_active Expired - Fee Related
- 2000-03-17 CN CN00807688A patent/CN1353603A/zh active Pending
- 2000-03-17 PL PL00350919A patent/PL350919A1/xx not_active Application Discontinuation
- 2000-03-17 SK SK1335-2001A patent/SK13352001A3/sk unknown
- 2000-03-17 TR TR2001/02695T patent/TR200102695T2/xx unknown
- 2000-03-17 WO PCT/US2000/007130 patent/WO2000056313A1/en not_active Application Discontinuation
- 2000-03-17 EP EP00916480A patent/EP1162965A1/en not_active Withdrawn
- 2000-03-17 BR BR0009159-6A patent/BR0009159A/pt not_active Application Discontinuation
- 2000-03-17 IL IL14524100A patent/IL145241A0/xx unknown
- 2000-03-17 NZ NZ514009A patent/NZ514009A/xx not_active Application Discontinuation
- 2000-03-17 HU HU0200393A patent/HUP0200393A2/hu unknown
- 2000-03-17 AU AU37578/00A patent/AU3757800A/en not_active Abandoned
- 2000-03-17 JP JP2000606218A patent/JP2002539251A/ja not_active Withdrawn
- 2000-03-17 CZ CZ20013283A patent/CZ291864B6/cs not_active IP Right Cessation
- 2000-03-17 MX MXPA01009467A patent/MXPA01009467A/es unknown
- 2000-03-17 KR KR1020017011925A patent/KR20020000784A/ko not_active Application Discontinuation
- 2000-03-17 CA CA002367021A patent/CA2367021A1/en not_active Abandoned
-
2001
- 2001-09-14 NO NO20014480A patent/NO20014480L/no unknown
- 2001-09-18 ZA ZA200107692A patent/ZA200107692B/en unknown
- 2001-10-10 BG BG105997A patent/BG105997A/xx unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101626768B (zh) * | 2006-09-15 | 2013-08-21 | 雷维瓦药品公司 | 环烷基甲胺的合成、使用方法和组合物 |
Also Published As
Publication number | Publication date |
---|---|
TR200102695T2 (tr) | 2002-01-21 |
BR0009159A (pt) | 2001-12-26 |
NO20014480D0 (no) | 2001-09-14 |
EP1162965A1 (en) | 2001-12-19 |
NZ514009A (en) | 2001-09-28 |
JP2002539251A (ja) | 2002-11-19 |
CA2367021A1 (en) | 2000-09-28 |
SK13352001A3 (sk) | 2002-03-05 |
BG105997A (en) | 2002-06-28 |
CZ291864B6 (cs) | 2003-06-18 |
HUP0200393A2 (en) | 2002-08-28 |
ZA200107692B (en) | 2002-12-18 |
AU3757800A (en) | 2000-10-09 |
MXPA01009467A (es) | 2004-03-19 |
IL145241A0 (en) | 2002-06-30 |
WO2000056313A1 (en) | 2000-09-28 |
KR20020000784A (ko) | 2002-01-05 |
PL350919A1 (en) | 2003-02-10 |
CZ20013283A3 (cs) | 2002-07-17 |
US6376552B1 (en) | 2002-04-23 |
NO20014480L (no) | 2001-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1188120C (zh) | 治疗饮食紊乱的方法 | |
CN1070698C (zh) | 医药治疗 | |
CN1231605A (zh) | 西布茶明类似物降低脂含量的用途 | |
EP1039900B1 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
CN1353603A (zh) | 控制与治疗药物有关的体重增加的方法 | |
SK32199A3 (en) | Use of sibutramine analogues for producing drug to lower uric acid levels and pharmaceutical composition containing mentioned analogues | |
WO2000056318A1 (en) | Treatment of neuropathic pain or fibromyalgia | |
CN1161114C (zh) | 一种治疗睡眠障碍的化合物在制药中的用途 | |
US6372797B1 (en) | Treatment of menstrual function | |
US20040198837A1 (en) | Treatment of neuropathic pain or fibromyalgia | |
US6403650B1 (en) | Treatment of pulmonary hypertension | |
CN1352552A (zh) | 关于骨关节炎的治疗 | |
US20030008897A1 (en) | Method of controlling weight gain associated with therapeutic drugs | |
WO2000056322A1 (en) | Treatment to lower platelet adhesiveness | |
WO2000056319A1 (en) | Treatment of orthostatic hypotension | |
CN1376061A (zh) | 关于食管裂孔疝的治疗 | |
CN1352553A (zh) | 怀孕后的减肥 | |
CN1399545A (zh) | 治疗某些与体重增加有关的癌症 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |